Brief reports: Fluoxetine in panic disorder

Franklin R. Schneier, Michael R. Liebowitz, Sharon O. Davies, Janet Fairbanks, Eric Hollander, Raphael Campeas, Donald F. Klein

Research output: Contribution to journalArticle

150 Scopus citations

Abstract

Twenty-five patients with a primary DSM-III-R diagnosis of panic disorder with or without agoraphobia were treated openly with the serotonin uptake inhibitor fluoxetine for up to 12 months. For most patients, treatment was initiated at 5 mg/day to minimize adverse effects previously reported with initiation at higher doses. Nineteen (76%) experienced moderate to marked improvement in panic attacks. Four (16%) were unable to tolerate fluoxetine due to adverse effects. Initiating treatment of panic disorder with low doses of fluoxetine may increase its acceptability and permit more patients to benefit from fluoxetine.

Original languageEnglish (US)
Pages (from-to)119-121
Number of pages3
JournalJournal of Clinical Psychopharmacology
Volume10
Issue number2
DOIs
StatePublished - Apr 1990
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Brief reports: Fluoxetine in panic disorder'. Together they form a unique fingerprint.

  • Cite this

    Schneier, F. R., Liebowitz, M. R., Davies, S. O., Fairbanks, J., Hollander, E., Campeas, R., & Klein, D. F. (1990). Brief reports: Fluoxetine in panic disorder. Journal of Clinical Psychopharmacology, 10(2), 119-121. https://doi.org/10.1097/00004714-199004000-00007